These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37482560)

  • 1. Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
    Recourt K; de Boer P; van der Ark P; Benes H; van Gerven JMA; Ceusters M; van Nueten L; Drevets WC; Bhatacharya A; Browning M; Jacobs GE
    Transl Psychiatry; 2023 Jul; 13(1):266. PubMed ID: 37482560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
    Recourt K; van der Aart J; Jacobs G; de Kam M; Drevets W; van Nueten L; Kanhai K; Siebenga P; Zuiker R; Ravenstijn P; Timmers M; van Gerven J; de Boer P
    J Psychopharmacol; 2020 Sep; 34(9):1030-1042. PubMed ID: 32248747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia.
    Bhattacharya A; Lord B; Grigoleit JS; He Y; Fraser I; Campbell SN; Taylor N; Aluisio L; O'Connor JC; Papp M; Chrovian C; Carruthers N; Lovenberg TW; Letavic MA
    Neuropsychopharmacology; 2018 Dec; 43(13):2586-2596. PubMed ID: 30026598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
    Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
    J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567.
    Bhattacharya A; Wang Q; Ao H; Shoblock JR; Lord B; Aluisio L; Fraser I; Nepomuceno D; Neff RA; Welty N; Lovenberg TW; Bonaventure P; Wickenden AD; Letavic MA
    Br J Pharmacol; 2013 Oct; 170(3):624-40. PubMed ID: 23889535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
    Lord B; Aluisio L; Shoblock JR; Neff RA; Varlinskaya EI; Ceusters M; Lovenberg TW; Carruthers N; Bonaventure P; Letavic MA; Deak T; Drinkenburg W; Bhattacharya A
    J Pharmacol Exp Ther; 2014 Dec; 351(3):628-41. PubMed ID: 25271258
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K
    J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder.
    Recourt K; de Boer P; Zuiker R; Luthringer R; Kent J; van der Ark P; Van Hove I; van Gerven J; Jacobs G; van Nueten L; Drevets W
    Transl Psychiatry; 2019 Sep; 9(1):216. PubMed ID: 31481683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors.
    Yue N; Huang H; Zhu X; Han Q; Wang Y; Li B; Liu Q; Wu G; Zhang Y; Yu J
    J Neuroinflammation; 2017 May; 14(1):102. PubMed ID: 28486969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder.
    Nakonezny PA; Carmody TJ; Morris DW; Kurian BT; Trivedi MH
    Int Clin Psychopharmacol; 2010 Nov; 25(6):328-33. PubMed ID: 20805756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression.
    Kent JM; Daly E; Kezic I; Lane R; Lim P; De Smedt H; De Boer P; Van Nueten L; Drevets WC; Ceusters M
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jun; 67():66-73. PubMed ID: 26804646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder.
    Bonaventure P; Dugovic C; Kramer M; De Boer P; Singh J; Wilson S; Bertelsen K; Di J; Shelton J; Aluisio L; Dvorak L; Fraser I; Lord B; Nepomuceno D; Ahnaou A; Drinkenburg W; Chai W; Dvorak C; Sands S; Carruthers N; Lovenberg TW
    J Pharmacol Exp Ther; 2012 Aug; 342(2):429-40. PubMed ID: 22570363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1
    Ruiz-Ruiz C; García-Magro N; Negredo P; Avendaño C; Bhattacharya A; Ceusters M; García AG
    Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 33174532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of
    Kolb HC; Barret O; Bhattacharya A; Chen G; Constantinescu C; Huang C; Letavic M; Tamagnan G; Xia CA; Zhang W; Szardenings AK
    J Nucl Med; 2019 Aug; 60(8):1154-1159. PubMed ID: 30733317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.
    Trivedi MH; Rush AJ; Ibrahim HM; Carmody TJ; Biggs MM; Suppes T; Crismon ML; Shores-Wilson K; Toprac MG; Dennehy EB; Witte B; Kashner TM
    Psychol Med; 2004 Jan; 34(1):73-82. PubMed ID: 14971628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroacupuncture Relieves Nerve Injury-Induced Pain Hypersensitivity via the Inhibition of Spinal P2X7 Receptor-Positive Microglia.
    Xu J; Chen XM; Zheng BJ; Wang XR
    Anesth Analg; 2016 Mar; 122(3):882-892. PubMed ID: 26599792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant effects of acute sleep deprivation are reduced in highly controlled environments.
    Goldschmied JR; Boland E; Palermo E; Barilla H; Dinges DF; Detre JA; Basner M; Sheline YI; Rao H; Gehrman P
    J Affect Disord; 2023 Nov; 340():412-419. PubMed ID: 37553017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Evaluation of a P2X7 Receptor-Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates.
    Ory D; Celen S; Gijsbers R; Van Den Haute C; Postnov A; Koole M; Vandeputte C; Andrés JI; Alcazar J; De Angelis M; Langlois X; Bhattacharya A; Schmidt M; Letavic MA; Vanduffel W; Van Laere K; Verbruggen A; Debyser Z; Bormans G
    J Nucl Med; 2016 Sep; 57(9):1436-41. PubMed ID: 27199364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic sleep deprivation for major depressive disorder: A randomized controlled trial.
    Xu YH; Wu F; Yu S; Guo YN; Zhao RR; Zhang RL
    J Affect Disord; 2024 Sep; 361():10-16. PubMed ID: 38844163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages.
    Gicquel T; Victoni T; Fautrel A; Robert S; Gleonnec F; Guezingar M; Couillin I; Catros V; Boichot E; Lagente V
    Clin Exp Pharmacol Physiol; 2014 Apr; 41(4):279-86. PubMed ID: 24472059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.